Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Return on Sales: 2021-2025

Historic Return on Sales for Foghorn Therapeutics (FHTX) over the last 5 years, with Sep 2025 value amounting to -3.06%.

  • Foghorn Therapeutics' Return on Sales rose 52.00% to -3.06% in Q3 2025 from the same period last year, while for Sep 2025 it was -3.06%, marking a year-over-year increase of 52.00%. This contributed to the annual value of -3.83% for FY2024, which is 95.00% down from last year.
  • According to the latest figures from Q3 2025, Foghorn Therapeutics' Return on Sales is -3.06%, which was up 4.78% from -3.21% recorded in Q2 2025.
  • Foghorn Therapeutics' 5-year Return on Sales high stood at -2.46% for Q2 2024, and its period low was -152.79% during Q1 2021.
  • Moreover, its 3-year median value for Return on Sales was -3.21% (2025), whereas its average is -3.56%.
  • As far as peak fluctuations go, Foghorn Therapeutics' Return on Sales spiked by 13,140bps in 2022, and later crashed by 95bps in 2024.
  • Over the past 5 years, Foghorn Therapeutics' Return on Sales (Quarterly) stood at -77.82% in 2021, then skyrocketed by 7,215bps to -5.66% in 2022, then surged by 278bps to -2.88% in 2023, then slumped by 95bps to -3.83% in 2024, then soared by 52bps to -3.06% in 2025.
  • Its last three reported values are -3.06% in Q3 2025, -3.21% for Q2 2025, and -3.48% during Q1 2025.